Los Angeles Capital Management LLC Boosts Stock Position in Heron Therapeutics, Inc. (NASDAQ:HRTX)

Los Angeles Capital Management LLC increased its stake in Heron Therapeutics, Inc. (NASDAQ:HRTX) by 49.9% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 514,377 shares of the biotechnology company’s stock after purchasing an additional 171,250 shares during the quarter. Los Angeles Capital Management LLC’s holdings in Heron Therapeutics were worth $874,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in HRTX. Rubric Capital Management LP grew its holdings in Heron Therapeutics by 127.3% during the 3rd quarter. Rubric Capital Management LP now owns 26,713,503 shares of the biotechnology company’s stock valued at $27,515,000 after buying an additional 14,963,503 shares in the last quarter. Congress Park Capital LLC grew its stake in Heron Therapeutics by 205.3% during the fourth quarter. Congress Park Capital LLC now owns 1,798,650 shares of the biotechnology company’s stock valued at $3,058,000 after acquiring an additional 1,209,500 shares in the last quarter. Adage Capital Partners GP L.L.C. increased its holdings in Heron Therapeutics by 100.0% during the 3rd quarter. Adage Capital Partners GP L.L.C. now owns 2,000,000 shares of the biotechnology company’s stock worth $2,060,000 after acquiring an additional 1,000,000 shares during the period. Tejara Capital Ltd lifted its stake in Heron Therapeutics by 28.6% in the 3rd quarter. Tejara Capital Ltd now owns 2,109,681 shares of the biotechnology company’s stock worth $2,173,000 after purchasing an additional 469,548 shares in the last quarter. Finally, Monaco Asset Management SAM boosted its holdings in Heron Therapeutics by 72.1% in the 3rd quarter. Monaco Asset Management SAM now owns 696,908 shares of the biotechnology company’s stock valued at $718,000 after purchasing an additional 291,908 shares during the period. 80.01% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on HRTX. Capital One Financial assumed coverage on shares of Heron Therapeutics in a report on Tuesday, April 23rd. They issued an “overweight” rating and a $6.00 price target on the stock. StockNews.com raised Heron Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, January 16th. Finally, Needham & Company LLC reissued a “buy” rating and set a $5.00 price objective on shares of Heron Therapeutics in a report on Wednesday.

Heron Therapeutics Stock Performance

Shares of NASDAQ:HRTX opened at $2.94 on Friday. The firm has a market capitalization of $442.87 million, a PE ratio of -3.42 and a beta of 1.73. Heron Therapeutics, Inc. has a 52-week low of $0.50 and a 52-week high of $3.22. The firm has a fifty day moving average of $2.73 and a 200 day moving average of $2.09.

Heron Therapeutics (NASDAQ:HRTX) last posted its quarterly earnings data on Tuesday, March 12th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.08. The firm had revenue of $34.23 million during the quarter, compared to analysts’ expectations of $30.98 million. On average, sell-side analysts forecast that Heron Therapeutics, Inc. will post -0.24 EPS for the current fiscal year.

About Heron Therapeutics

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.